Abstract
Cetirizine, a potent Hrantagonist, has been reported to inhibit eosinophil migration into human skin. We, therefore, further evaluated the effect of cetirizine on eosinophil function, including superoxide anion generation, chemotaxis, and eosinophil peroxidase (EP) release. In allergic subjects, superoxide anion generation 60 min after platelet-activating factor (PAF) activation was inhibited by concentrations of cetirizine ranging from 0.01 to 1 μg/ml (2.612 ×10-8 to 2.612 × 10-6 M). No significant inhibition was observed in normal subjects. PAF (10-6 M)-induced eosinophil chemotaxis was also inhibited by cetirizine. In allergic subjects, percent inhibitions were 47.5±6.1% at 0.01 μg/ml, 50.8±5.1% at 0.1 μg/ml and 58.9±6.4% at 1 (μg/ml of cetirizine. In allergic subjects, N-formyl-methionyl-lencyl-phenylalanine induced eosinophil chemotaxis was inhibited by cetirizine, although EP release was not. These results suggest cetirizine has effects on eosinophils which can not be explained by H1.
| Original language | English |
|---|---|
| Pages (from-to) | 384-390 |
| Number of pages | 7 |
| Journal | International Archives of Allergy and Immunology |
| Volume | 103 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1994 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology
- Immunology and Allergy
Cite this
Effect of cetirizine on human eosinophil superoxide generation, eosinophil chemotaxis and eosinophil peroxidase in vitro. / Okada, Chiharu; Eda, Ryosuke; Miyagawa, Hidefumi; Sugiyama, Haruhito; Hopp, Russell J.; Bewtra, Againdra K.; Townley, Robert G.
In: International Archives of Allergy and Immunology, Vol. 103, No. 4, 1994, p. 384-390.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of cetirizine on human eosinophil superoxide generation, eosinophil chemotaxis and eosinophil peroxidase in vitro
AU - Okada, Chiharu
AU - Eda, Ryosuke
AU - Miyagawa, Hidefumi
AU - Sugiyama, Haruhito
AU - Hopp, Russell J.
AU - Bewtra, Againdra K.
AU - Townley, Robert G.
PY - 1994
Y1 - 1994
N2 - Cetirizine, a potent Hrantagonist, has been reported to inhibit eosinophil migration into human skin. We, therefore, further evaluated the effect of cetirizine on eosinophil function, including superoxide anion generation, chemotaxis, and eosinophil peroxidase (EP) release. In allergic subjects, superoxide anion generation 60 min after platelet-activating factor (PAF) activation was inhibited by concentrations of cetirizine ranging from 0.01 to 1 μg/ml (2.612 ×10-8 to 2.612 × 10-6 M). No significant inhibition was observed in normal subjects. PAF (10-6 M)-induced eosinophil chemotaxis was also inhibited by cetirizine. In allergic subjects, percent inhibitions were 47.5±6.1% at 0.01 μg/ml, 50.8±5.1% at 0.1 μg/ml and 58.9±6.4% at 1 (μg/ml of cetirizine. In allergic subjects, N-formyl-methionyl-lencyl-phenylalanine induced eosinophil chemotaxis was inhibited by cetirizine, although EP release was not. These results suggest cetirizine has effects on eosinophils which can not be explained by H1.
AB - Cetirizine, a potent Hrantagonist, has been reported to inhibit eosinophil migration into human skin. We, therefore, further evaluated the effect of cetirizine on eosinophil function, including superoxide anion generation, chemotaxis, and eosinophil peroxidase (EP) release. In allergic subjects, superoxide anion generation 60 min after platelet-activating factor (PAF) activation was inhibited by concentrations of cetirizine ranging from 0.01 to 1 μg/ml (2.612 ×10-8 to 2.612 × 10-6 M). No significant inhibition was observed in normal subjects. PAF (10-6 M)-induced eosinophil chemotaxis was also inhibited by cetirizine. In allergic subjects, percent inhibitions were 47.5±6.1% at 0.01 μg/ml, 50.8±5.1% at 0.1 μg/ml and 58.9±6.4% at 1 (μg/ml of cetirizine. In allergic subjects, N-formyl-methionyl-lencyl-phenylalanine induced eosinophil chemotaxis was inhibited by cetirizine, although EP release was not. These results suggest cetirizine has effects on eosinophils which can not be explained by H1.
UR - http://www.scopus.com/inward/record.url?scp=0028295046&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028295046&partnerID=8YFLogxK
U2 - 10.1159/000236658
DO - 10.1159/000236658
M3 - Article
C2 - 8130652
AN - SCOPUS:0028295046
VL - 103
SP - 384
EP - 390
JO - International Archives of Allergy and Immunology
JF - International Archives of Allergy and Immunology
SN - 1018-2438
IS - 4
ER -